6 / 22
Page 29
Notes:
conferenceseries
.com
6
th
World Congress on
October 16-18, 2017 | San Francisco, USA
Breast Cancer & Therapy
Volume 2, Issue 5 (Suppl)
Breast Can Curr Res, an open access journal
Breast Cancer Congress 2017
October 16-18, 2017
Harnessing benefits from targeting tumor associated carbohydrate antigens
Thomas Kieber-Emmons
University of Arkansas for Medical Sciences, USA
I
ntegrating additive or synergistic antitumor effects that focus on distinct elements of tumor biology are the most rational
of strategies for cancer treatment. The real challenge is to define what elements of tumor biology make the most sense to be
targeted. Signal transduction (pathways) can define therapeutic strategies and approaches that might be tailored to harness benefit
from sustained immunity much like that observed from natural antibodies involved in immune surveillance mechanisms. Tumor
Associated Carbohydrate Antigens (TACAs) are pan-targets on tumor cells because they play roles in initiation and metastases of
cancer, and considered as common targets shared by many tumor types, and regulating a network of signaling pathways associated
with cell survival. Strategies that target TACAs therefore have potential benefit as cell death therapies. We have been developing an
active immunization strategy targeting TACAs using carbohydrate mimetic peptides (CMP) designed as pan-immunogens. One
CMP called P10s was computer designed to induce anti-GD2 and anti-LeY antibodies with the intent of inducing multiple sets
of antibodies reactive with multiple TACAs when immunizing with a single agent. We have completed a Phase I clinical trial in
breast cancer with a CMP, showing that this designed CMP can induce proapoptotic antibodies in humans that can sensitize tumor
cells to chemotherapeutics. We have progressed to a Phase II trial in the neoadjuvant setting where we observe tumor shrinkage in
combination therapy.
Biography
Thomas Kieber-Emmons is a Professor of Pathology, is Co-Leader of the Therapeutic Sciences Program at the Winthrop P Rockefeller Cancer Institute and holds the
Josetta Wilkins Endowed Chair in Breast Cancer Research. He obtained his PhD in Biophysics and Molecular Immunology at the Roswell Park Cancer Institute applying
structural immunology design principles to develop antibody based immunogens. He is known for his work on developing carbohydrate mimetic peptides (CMPs) as vac-
cines in both the cancer and pathogen areas and is an acknowledged pioneer in this field. His work reflects one of the very true bench-to-bedside initiatives as a CMP
immunogen is in several Phase 2 clinical trials.
tke@uams.eduThomas Kieber-Emmons, Breast Can Curr Res 2017, 2:5 (Suppl)
DOI: 10.4172/2572-4118-C1-011